Clinical trials: High-risk Breast Cancer
HER2-positive Breast Cancer
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and easy recurrence and metastasis.
- Trial name
- TaxCbHER2 (NCT06722612)
- Where
- China
- Volunteers
- 2,916 people
- Sponsor
- Shu Wang
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Peripheral stem cell transplantation combined with biological therapy may be an effective treatment for breast…
- Trial name
- NCT00002616
- Testing
- aldesleukin, filgrastim, carboplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Illinois Chicago
Breast Neoplasms, Ovarian Neoplasms
Outcomes of Education and Counseling for BRCA1 Testing
This study will identify how personal beliefs, values and family experiences affect a person's decision as to whether or not to be tested for changes in a gene called BRCA1 or BRCA2.
- Trial name
- NCT00001468
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Breast Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- 15-95 (NCT00002784)
- Testing
- filgrastim, CMF regimen, cyclophosphamide
- Where
- 11 sites in Australia, Switzerland
- Volunteers
- 344 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Hereditary Cancer Syndrome
CfDNA in Hereditary And High-risk Malignancies 2
The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes.
- Trial name
- CHARM2 (NCT06726642)
- Testing
- Cell-free DNA analysis
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people
- Sponsor
- University Health Network, Toronto
Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound, Triple Negative Breast Cancer (TNBC)
Expanded Access to Veliparib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to veliparib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound, Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Cancer, Patients Requiring Veliparib Suspension Formulation
- Trial name
- NCT03123211
- Testing
- Veliparib
- Sponsor
- AbbVie
Cancer
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
RATIONALE: Giving donor natural killer cells to patients who have undergone donor bone marrow transplant may make the transplant work better and keep cancer cells from coming back.
- Trial name
- NCT00569283
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Asan Medical Center
Breast Cancer
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003032
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 25 sites in Canada
- Volunteers
- 224 people
- Sponsor
- NCIC Clinical Trials Group
Ovarian Neoplasm Epithelial, Hereditary Breast and Ovarian Cancer Syndrome
Inherited Susceptible Genes Among Epithelial Ovarian Cancer
Purpose: To investigate the prevalence of the germline mutations in the BRCA 1/2 and mismatch repair genes in patients with epithelial ovarian cancer (EOC) and their relatives, and related somatic mutations in tumor tissues in…
- Trial name
- NCT03015376
- Where
- 2 sites in China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer, Magnetic Resonance Imaging
Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women
Use Convolutional Neural Networks Analysis for Classification of Contrast-enhancing Lesions at Multiparametric Breast MRI. Build an abbreviated protocal, and investigate whether an abbreviated protocol was suitable for breast…
- Trial name
- NCT04996615
- Testing
- no intervention
- Where
- 2 sites in China
- Volunteers
- 5,000 people
- Sponsor
- Peking University People's Hospital
Cancer
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients
RATIONALE: Liposomal amphotericin B may be effective in controlling fever and granulocytopenia. It is not yet known which regimen of liposomal amphotericin B is more effective in treating cancer patients who have these…
- Trial name
- NCT00003938
- Testing
- liposomal amphotericin B
- Where
- 24 sites in Belgium, Czechia and 13 more
- Volunteers
- 115 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004092
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- City of Hope Medical Center
Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.
- Conditions
- Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer, Solid Tumors, NUT Midline Carcinoma
- Trial name
- NCT02307240
- Testing
- CUDC-907
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Curis, Inc.
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer.
- Trial name
- NCT00014222
- Testing
- epoetin alfa, filgrastim, cyclophosphamide
- Where
- 78 sites in United States, Canada
- Volunteers
- 2,104 people
- Sponsor
- NCIC Clinical Trials Group
Triple Negative Breast Cancer
Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies
This project introduces a novel methodology for the in-depth immunogenetic characterization of the TR gene repertoire in solid tumors, holding the promise to offer unprecedented insights into the TR anti-tumor specificity and the…
- Trial name
- NCT06646263
- Where
- Greece
- Volunteers
- 150 people
- Sponsor
- Institute of Applied Biosciences
Breast Cancer
Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.
The purpose of the study is to to compare low dose of exemestane (babyexe) versus low dose of tamoxifen (babytam) in terms of change of quality of life from baseline to 12 months.
- Trial name
- BabyTears (NCT06364267)
- Testing
- Tamoxifen 10 MG, Exemestane 25 MG
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Andrea DeCensi
Breast Cancer, Healthy
Susceptibility to Breast Cancer
This study will explore whether different forms, or variants, of genes are related to a person s risk of developing breast cancer.
- Trial name
- NCT00004565
- Where
- United States
- Volunteers
- 737 people
- Sponsor
- National Cancer Institute (NCI)